PT 150
Alternative Names: ORG-34517; PT150; SCH-900636Latest Information Update: 28 Jun 2024
At a glance
- Originator Organon
- Developer Merck & Co; Organon; Pop Test
- Class Antidepressants; Antineoplastics; Benzodioxoles; Chemosensitisers; Phenanthrenes; Steroids
- Mechanism of Action Androgen receptor antagonists; Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alcoholism; Breast cancer; Cancer
- Discontinued Major depressive disorder
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Jan 2024 No recent reports of development identified for phase-I development in Alcoholism(In adults) in USA (PO)
- 27 Oct 2023 Pop Test completes a phase I PT150 PK trial in Alcoholism (In volunteers) in USA (NCT04331288)